[go: up one dir, main page]

WO2011161263A1 - Compositions pharmaceutiques destinées à une administration par voie cutanée - Google Patents

Compositions pharmaceutiques destinées à une administration par voie cutanée Download PDF

Info

Publication number
WO2011161263A1
WO2011161263A1 PCT/EP2011/060699 EP2011060699W WO2011161263A1 WO 2011161263 A1 WO2011161263 A1 WO 2011161263A1 EP 2011060699 W EP2011060699 W EP 2011060699W WO 2011161263 A1 WO2011161263 A1 WO 2011161263A1
Authority
WO
WIPO (PCT)
Prior art keywords
semi
pharmaceutical composition
solid pharmaceutical
potency
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/060699
Other languages
English (en)
Inventor
Hilde Adi Pierrette Revets
Ann Debunne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of WO2011161263A1 publication Critical patent/WO2011161263A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the field of invention relates to semi-solid pharmaceutical compositions for administration onto the skin comprising immunoglobulin single variable domains or constructs thereof.
  • compositions such as semi-solid pharmaceutical compositions comprising immunoglobuli single variable domains or constructs thereof to the skin of an animal such as a human (also herein referred to as "cutaneous administration")
  • cutaneous administration can be used i) to avoid systemic side effects when high doses are required at a localized area, e.g. psoriasis treatment, or ii) as an alternative systemic administration route, in order to e.g. avoid hepatic processing.
  • a pharmaceutical compositions with a high amount of the active principle such as an immunoglobulin single variable domain or construct thereof directed against a therapeutic target, is desirable in order to minimize the frequency of administration and the amount of the pharmaceutical composition that needs to be applied.
  • semi-solid pharmaceutical compositions with a high amount of immunoglobulin single variable domains or constructs thereof pose several problems.
  • One problem is the instability due to degradation or variant formation of the immunoglobulin. With the addition of sucrose and appropriate buffers (e.g. WO 2011/026948) or sequence optimization of the immunoglobulin single variable domain (e.g. WO 2009/095235), this problem has been addressed to a certain, extent for liquids.
  • the long term stability of immunoglobulin single variable domains in semi-solid pharmaceutical composition has not been explored and it is unclear whether such an approach that had some success for liquids will hold true also for semi-solid pharm ceutical compositions.
  • Another problem is the instability due to the formation of protein aggregates in particular at high concentration of the protein.
  • Emulsifying agents such as surfactants have been reported to help to minimize this issue in liquid solutions.
  • US7147854 discloses some optimized topical pharmaceutical compositions containing surfactants and conventional antibodies but also indicate that their stability is not sufficient for long term storage or long term applications (see Table 17: Data from the accelerated stability test).
  • immunoglobulin single variable domains in combinations with non ionic surfactants are particularly suited for concentrated semi-solid pharmaceutical compositions for cutaneous use.
  • said pharmaceutical composition may further be complemented with sugar, i.e. in particular with high amounts of sugar (in order to stabilize the polypeptides).
  • the invention provides semi-solid pharmaceutical compositions for the administration of therapeutic molecules comprising immunoglobulin variable domain(s).
  • the semi-solid pharmaceutical compositions allow for the local and/or systemic delivery of the therapeutic molecules comprising immunoglobulin variable domain(s).
  • the semi -solid pharmaceutical compositions can be deli ered locally to the skin, for instance in order to treat psoriasis or other skin diseases, by administering an effective dose of the semi-solid pharmaceutical composition in an effective interval directly to the diseased skin and the semi-solid pharmaceutical, composition comprises the one or more therapeutic molecules that include one or more immunoglobulin variable domains.
  • the semi-soiid pharmaceutical compositions allow for the systemic delivery of the therapeutic molecules by non-invasive means.
  • the semi-soiid pharmaceutical composition comprises one or more excipients.
  • Excipients provide the physical environment for the delivery of the therapeutic molecules as a semi-solid pharmaceutical composition. It was surprisingly found, as described herein, that immunoglobulin single variable domain-based therapeutic molecules could be formulated at a high amount of the total mass of the pharmaceutical composition, while retaining stability, solubility, and potency (such as molecule integrity and functional such as inhibiting properties) of the unformulated therapeutic molecule. Accordingly, in a preferred aspect, the immunoglobulin variable domain is an immunoglobulin single variable domain.
  • Fig. 1 shows a SEC chromatogram of a PBS extract of a cream containing the P231L0075 Nanobody construct, after 8 weeks storage at 4°C. An overlay with the reference sample, the liquid pharmaceutical composition stored at -20°C, is shown. After storage a small increase of the percentage oligomers was detected.
  • Fig. 2 shows an RPC chromatogram of a PBS extract of a cream containing the P23IL0075 Nanobody construct, after 8 weeks storage at 4°C. An overlay with the reference sample, the liquid pharmaceutical composition stored at -20°C, is shown. After storage a very small increase of some impurities was detected.
  • Fig. 3 shows a SEC chromatogram of a PBS extract of a cream containing the P231L0087 Nanobody construct, after 4 weeks storage at 25°C. An overlay with the reference sample, the liquid pharmaceutical composition stored at -20°C, is shown. After storage a small increase of the percentage oligomers was detected.
  • Fig. 4 shows a RPC chromatogram of a PBS extract of a cream containing P231L0087 Nanobody construct, after 4 weeks storage at 25°C. An overlay with the reference sample, the liquid pharmaceutical composition stored at -20°C, is shown. After storage an increase of the relative amount of impurities was detected.
  • Fig. 9 shows the inhibition of IL-23 binding to IL-23R by the P23IL0075 Nanobody construct after being formulated in cream.
  • Fig. 1 1 shows the inhibition of IL-23 binding to IL-23R by the P23IL0087 Nanobody construct after being formulated in cream.
  • the invention provides semi-solid pharmaceutical compositions for cutaneous administration of therapeutic molecules comprising immunoglobulin variable domains, and therapeutic molecules based on other protein scaffolds, without significantly compromising stability or biological activity, in certain aspects, the invention provides semisolid pharmaceutical compositions and methods for the administration of therapeutic- molecules that include one or more immunoglobulin single variable domains, or other protein scaffolds, and constructs thereof.
  • the semi -solid pharmaceutical compositions including one or more therapeutic molecules and one or more excipients are provided.
  • the one or more therapeutic molecules may include any immunoglobulin, variable domains, and preferably one or more immunoglobulin single variable domains.
  • the semi-solid pharmaceutical compositions include at least 10 mg of the one or more therapeutic molecules per g semi-solid pharmaceutical compositions, and the one or more therapeutic molecules include one or more immunoglobulin variable domains, such as one or more immunoglobulin single variable domains.
  • the semi-solid pharmaceutical composition includes at least 15 mg, more preferably 20 mg, more preferably 25 mg, more preferably 30 mg, more preferably 40 mg or even more preferably 50 mg of the one or more therapeutic molecules per gram of said semi-solid pharmaceutical composition.
  • the invention provides semi-solid pharmaceutical compositions for the administration of therapeutic molecules comprising immunoglobulin variable domain(s). such as immunoglobulin single variable domains.
  • the semi-solid pharmaceutical compositions allow for the local delivery of the therapeutic molecules comprising immunoglobulin variable domain(s). such as immunoglobulin single variable domains.
  • the semi-solid pharmaceutical, compositions can be delivered locally to the skin, for instance in order to treat psoriasis or other skin diseases, by administering an effective dose of the semisolid pharmaceutical composition in an effective interval directly to the diseased skin and the semi-solid pharmaceutical composition comprises the one or more therapeutic molecules that include one or more immunoglobulin variable domains, such as immunoglobulin single variable domains.
  • the semi-solid phaimaceutical compositions allow for the delivery of the therapeutic molecules by non-invasive means.
  • the semi-solid pharmaceutical composition comprises one or more excipients. Excipients provide the physical environment for the delivery of the therapeutic molecules as a semi-solid pharmaceutical composition. It was surprisingly found, as described herein, that
  • immunoglobulin single variable domain-based therapeutic molecules could be formulated at a high amount of the total mass of the pharmaceutical composition, while retaining stability, solubility, and potency (such as molecule integrity and functional such as inhibiting properties) of the unformulated therapeutic molecule.
  • the invention provides semi-solid pharmaceutical compositions for the administration of therapeutic molecules comprising immunoglobulin variable domain(s), such as immunoglobulin single variable domains.
  • the semi-solid pharmaceutical compositions allow for the transdermal delivery of the therapeutic molecules comprising immunoglobulin variable domain(s), such as immunoglobulin single variable domains.
  • the semi-solid pharmaceutical compositions can be transdermal ⁇ delivered by administering an. effective dose of the semi-solid pharmaceutical composition in an effective interval to the skin and the semi-solid pharmaceutical composition comprises the one or more therapeutic molecules that include one or more immunoglobulin variable domains, such as
  • the semi-solid In some embodiments the semi-solid
  • the semi-solid pharmaceutical composition comprises one or more excipients. Excipients provide the physical environment for the delivery of the therapeutic molecules as a semi-solid pharmaceutical composition. It was surprisingly found, as described herein, that immunoglobulin single variable domain-based therapeutic molecules could be formulated at a high percentage of the total mass of the pharmaceutical composition, while retaining stability, solubility, and potency (such as pharmacodynamic and
  • the invention provides for semi-solid pharmaceutical compositions with higher percentages of therapeutic molecules comprising immunoglobulin variable domains such as e.g. immunoglobulin single variable domains, and therapeutic molecules based on other protein scaffolds than previously described.
  • the invention also accordingly provides for semi-solid pharmaceutical compositions that are stable.
  • the methods of the invention allow for the prolonged delivery of more therapeutic molecules in a semi-solid
  • the semi-solid pharmaceutical compositions comprise one or multiple excipients.
  • the excipients used in the pharmaceutical composition can have a variety of functions, including, but not limited to, carriers, lyoprotectants, emulsifying agents, oil phase ingredients, viscosity adjusters and preservatives.
  • Suitable excipients are, in particular, pharmaceutically acceptable carriers which include, but are not limited to. a neutral sterile cream, a base cream., a gel, a jelly, an ointment, or a combination thereof.
  • the preferred pharmaceutically acceptable carrier is a base cream, which contains an emulsifying agent, an oil-phase ingredient, and a water-phase ingredient.
  • the preferred emulsifying agent includes, but is not limited to, a non- ionic surfactant, e.g. polyethylene glycol derivatives (e.g. cetomacrogol 1000) and polyoxyethylene derivatives such as polysorbate 20 or 80 alone or in combination with fatty alcohols such as cetyl alcohol, stearyl alcohol, and cerostearylalcohol.
  • a non- ionic surfactant e.g. polyethylene glycol derivatives (e.g. cetomacrogol 1000) and polyoxyethylene derivatives such as polysorbate 20 or 80 alone or in combination with fatty alcohols such as cetyl alcohol, stearyl alcohol, and cerostearylalcohol.
  • the preferred oil-phase ingredient includes, but is not limited to white vaselin, liquid paraffin, and dimethicone.
  • the preferred water-phase ingredient includes, but is not limited to water, glycerol and propyleneglycol.
  • the preferred preservative includes, but is not
  • the pharmaceutical composition may also contain suitable stabilizers or agents which increase the solubility of the compounds of the invention to allow for the preparation of highly concentrated solutions.
  • the preferred stabiliser includes, but is not limited to, carbohydrates such as sucrose, lactose and trehalose, sugar alcohols such as raannitol and sorbitol, amino acids such as histidine, glycine, phenylalanine and arginine.
  • a suitable buffer such as a histidine buffer may further stabilize and/or solubilize the compounds of the invention within the semi-solid formulation.
  • the preferred pharmaceutically acceptable cream formulation may help protect and maintain the activity of the immunoglobulin single variable domains and/or constructs thereof (also herein referred to as "compounds of the invention") for at least two years at appropriate temperature e.g. 4°C or room temperature.
  • the compounds of the invention may have undergone a sequence optimization procedure wherein (in particular) the framework residues will have been amended to minimize possible chemical instabilities such as e.g. the risk of pyroglutamate formation, oxidation or isomerization of the therapeutic molecules (reference is also made to methods described in WO 2009/095235, the content of which is hereby incoiporated in its entirety).
  • the semi-solid pharmaceutical compositions described herein can have a variety of concentrations.
  • the semi-solid pharmaceutical compositions used according to methods of the invention can be at least about 15 mg, more preferably at least about 20 mg, more preferably at least about 25 mg, more preferably at least about 30 mg, more preferably at least about 40 mg or even more preferably at least about 50 mg of the one or more therapeutic molecules per g said semi-solid pharmaceutical composition.
  • the pharmaceutical compositions described herein allow for a high drug load of the therapeutic molecules, the semi-solid pharmaceutical compositions provide, for example, for the delivery of at least about 0.1 mg therapeutic molecule per cm 2 or more such as e.g. between 0.01 to 0.5 mg therapeutic molecule or more per cm 2 .
  • the therapeutic molecules in the described pharmaceutical compositions have unexpectedly retained most of their integrity.
  • the integrity of the one or more therapeutic molecules at a concentration of at least about 20 mg of therapeutic molecules per gram semi-solid composition was greater than 95% when measured by either % main peak on SEC (see also experimental part example 3.3 for more details on measuring integrity, e.g. Table 5).
  • after formulation the integrity of the one or more therapeutic molecules at a concentration of at least about 20 mg per gram semi-solid composition was greater than 80% when measured by either % extraction recovery (see also experimental part 3.3 for more details on measuring integrity, e.g. Table 5). In some embodiments .
  • the integrity of the one or more therapeutic molecules at a concentration of at least about 20 mg per gram semi- solid composition was greater than 75% when measured by either % main peak on RPC (see also experimental part 3.3 for more details on measuring integrity, e.g. Table 5).
  • the tiierapeutic molecules in the described pharmaceutical compositions were unexpectedly stable and retained potency.
  • the potency of the one or more therapeutic molecul es was greater than 95% after formulation at a concentration of at least about 20 mg of therapeutic molecules per g semi-solid composition and storage at 25°C over 4 weeks (see also experimental part 4 and 5 for more details on measuring potency, e.g. Tables 6-13). In.
  • the potency of the one or more therapeutic molecules was greater than 99% after formulation at a concentration of at least about 20 nig of therapeutic molecules per g semi-solid composition and storage at 25°C over 4 weeks (see also experimental part example 5 for more details on measuring potency, e.g. Tables 9-13).
  • the therapeutic molecules are lyophilized prior to use in the pharmaceutical compositions described herein. Prior to the instant invention it was not recognized, or expected, that therapeutic molecules comprising immunoglobulin variable domains couid be lyophilized and reconstituted without loss of potency.
  • the invention provides pharmaceutical compositions for transdermal and/or local delivery of therapeutic molecules comprising immunoglobulin variable domains, such as immunoglobulin single variable domains.
  • the invention therefore provides methods for the systemic and/or local delivery of immunoglobulin variable domains using semi-solid pharmaceutical compositions. It was surprisingly found, as described herein, that the invention provides pharmaceutical compositions in which, after formulation, the potency of the one or more therapeutic molecules at a concentration, of at least about 20 mg per gram semi-solid composition is not affected, such as upon delivery to a subject.
  • a semi-solid pharmaceutical composition of 1 g comprising at least about 20 mg of therapeutic molecule, constructed and arranged as described herein, is capable of delivering to a subject at least about 0.1 mg therapeutic molecule per cm 2 or more such as e.g. between 0.01 to 0.5 mg therapeutic molecule or more per cm 2 .
  • Potency of the therapeutic molecule can be measured before preparation of the pharmaceutical composition, after preparation of the pharmaceutical composition, before administration and/or after administration of the pharmaceutical composition.
  • the binding properties of the therapeutic molecule can be measured using the methods and assays described in the examples below (see e.g. examples 4 and 5).
  • the therapeutic molecule has at least about 90% of the potency after preparation of the pharmaceutical composition as compared to prior to the preparation of the pharmaceutical composition.
  • the therapeutic molecule has at least about 90% of the potency after administration of the pharmaceutical composition as compared to prior to administration of the pharmaceutical composition.
  • the therapeutic molecule has at least about 90% of the potency after administration of the pharmaceutical composition as compared to prior to preparation of the pharmaceutical composition.
  • Potency of the therapeutic molecule in the pharmaceutical compositions described herein can be retained to levels (compared as described herein) of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or even to substantially 100% potency.
  • Therapeutic amount compared as described herein of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or even to substantially 100% potency.
  • An effective amount of therapeutic is a dosage of the therapeutic molecules comprising the immunoglobulin variable domain (or other protein scaffold) sufficient to provide a medically desirable result.
  • the effective amount will vary with the particular condition being treated, the age and physical condition of the subject being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration and other factors within the knowledge and expertise of the health practitioner.
  • an effective amount for treating a disease or condition would be an amount sufficient to lessen the progression of or inhibit the disease or condition, or its symptoms.
  • the invention provides methods, pharmaceutical compositions and devices for the administration, such as cutaneous administration, of therapeutic molecules comprising immunoglobulin variable domains.
  • the immunoglobulin variable domain (also referred to as ' mmunoglobulin, variable domain of the invention") is a VH, VL, VHH, camelized VH, camelized VL, or VHH that is optimized for stability, potency, manufacturability and similarity to human framework regions.
  • the immunoglobulin variable domain is a VHH that is optimized for stability, potency, manufacturability and similarity to human framework regions.
  • the therapeutic molecule comprises a multi valent and/or multispecific construct.
  • the term "immunoglobulin variable domain” is used as a genera] term to include heavy chain, variable domain sequences. More specifically, the immunoglobulin variable domains can be heavy chain variable domain sequences that are derived from a conventional four-chain antibody from e.g., human or heavy chain variable domain sequences that are derived from a heavy chain antibody from e.g., camels, dromedaries, alpacas or llamas, ccording to the invention, the immunoglobulin variable domains can be domain antibodies, or immunoglobulin sequences that are suitable for use as domain antibodies, single domain antibodies, or immunoglobulin sequences that are suitable for use as single domain antibodies or immunoglobulin sequences that are suitable for use as compounds termed "dAbs", or “Nanobodies” (NANOBODY® and NANOBODIES ⁇ are registered trademarks of Ablynx N.V.) in the field and preferably are NANOBODIES®.
  • Immunoglobulin variable domains include camelid derived immunoglobulin variable domains and functional, optimized variants thereof.
  • Functional and optimized variants include variants that bind the same epitope and variants that are optimized for better potency in binding, optimized for human framework regions, chemical stability and
  • the immunoglobulin variable domains provided by the invention are preferably in essentially isolated form (as defined herein), or form pari of a protein or polypeptide of the invention (as defined herein), which may comprise or essentially consist of one or more immunoglobulin variable domains of the in vention and which may optionally further comprise one or more further immunoglobulin variable domains (all optionally linked via one or more suitable linkers).
  • the one or more immunoglobulin variable domains of the invention may be used as a binding unit in such a protein or polypeptide, which may optionally contain one or more further immunoglobulin variable domains that can.
  • Such a protein or polypeptide may also be in essentially isolated form (as defined herein).
  • the invention includes immunoglobulin variable domains of different origin, comprising mouse, rat, rabbit, donkey, shark, human and camelid immunoglobulin variable domains.
  • the invention also includes fully human, humanized or chimeric immunoglobulin variable domains.
  • the invention comprises camelid immunoglobulin variable domains and humanized, camelid immunoglobulin variable domains, or camelized domain antibodies, e.g., camelized VH sequences such as described by Hamers et al. (see for example WO 94/04678; Davies and Riechmann (FEBS Lett. 339: 285-290, 1994 and Prat. Eng. 9(6): 531-537, 1996); and Muyldermans et al.
  • the invention comprises fused immunoglobulin variable domains, e.g., forming a multivalent and/ or multispecific construct (e.g., for multivalent and multispecific polypeptides containing one or more VHH domains and their preparation, reference is also made to Conrath et al, J. Biol. Chem., Vol. 276, 10. 7346-7350, 2001 , as well as to for example WO 96/34103 and WO 99/232 1), and immunoglobulin, variable domains comprising tags or other functional moieties, e.g., toxins, labels, radiochemicals, etc., which are derivable from the immunoglobulin variable domains of the present invention.
  • a multivalent and/ or multispecific construct e.g., for multivalent and multispecific polypeptides containing one or more VHH domains and their preparation, reference is also made to Conrath et al, J. Biol. Chem., Vol. 276, 10. 7346-7350, 2001 , as well as to for example
  • the immunoglobulin variable domain and structure of a immunoglobulin variable domain can - without however being limited thereto - be comprised of four framework regions or "PR's", which are referred to in the art and herein as “Framework region 1 " or “FR1”; as “Framework region 2" or “FR2”; as “Framework region 3” or “FR3”; and as “Framework region 4" or “FR4", respectively; which framework regions are interrupted by three complementary determining regions or "CDR's”, which are referred to in the art as "Complementarity Determining Region l"or "CDR1"; as “Complementarity Determining Region 2" or “CDR2”; and as “Complementarity Determining Region 3" or “CDR3", respectively.
  • CDR's complementary determining regions
  • the total number of amino acid residues in an immunoglobulin variable domain can be in the region of 1 10- 120, is preferably 1 12- 1 15, and is most preferably 1 13.
  • parts, fragments, analogs or derivatives (as further described herein) of a immunoglobulin variable domain are not particularly limited as to their length and/or size, as long as such parts, fragments, analogs or derivatives meet the further requirements outlined herein and are also preferably suitable for the purposes described herein.
  • immunoglobulin single variable domain defines molecules wherein the antigen binding site is present on, and formed by, a single immunoglobulin domain. This sets immunoglobulin single variable domains apart from “conventional” immunoglobulins or their fragments, wherein, two immunoglobulin domains, in particular two variable domains, interact to form an antigen binding site.
  • a heavy chain variable domain (VH) and a light chain variable domain (VL) interact to form an antigen binding site.
  • VH heavy chain variable domain
  • VL light chain variable domain
  • CDRs complementarity determining regions
  • immunoglobulin single variable domain In contrast, the binding site of an immunoglobulin single variable domain is formed by a single VH or VL dom in. Hence, the antigen binding site of an immunoglobulin single variable domain is formed by no more than three CDRs.
  • immunoglobulin single variable domain and single variable domain hence does not comprise conventional immunoglobulins or their fragments which require interaction of at least two variable domains for the formation of an antigen binding site. However, these terms do comprise fragments of conventional immunoglobulins wherein the antigen binding site is formed by a single variable domain.
  • the single variable domain may for example comprise a light chain variable domain sequence (e.g. a VL-sequence) or a suitable fragment thereof; or a heavy chain variable domain sequence (e.g. a VH-sequence or VHH sequence) or a suitable fragment thereof; as long as it is capable of forming a single antigen binding unit (i.e. a functional antigen binding unit thai essentially consists of the single variable domain, such that the single antigen binding domain does not need to interact with another variable domain to form a functional antigen binding unit, as is for example the case for the variable domains that are present in for example conventional antibodies and scFv fragments that need to interact with another variable domain - e.g. through a VH/VL interaction - to form a functional antigen binding domain).
  • a light chain variable domain sequence e.g. a VL-sequence
  • a heavy chain variable domain sequence e.g. a VH-sequence or VHH sequence
  • the immunoglobulin single variable domains are light chain variable domain sequences (e.g. a VL-sequence), or heavy chain, variable domain sequences (e.g. a VH-sequence); more specifically, the immunoglobulin single variable domains can be heavy chain variable domain sequences that are derived from a conventional four-chain antibody or heavy chain variable domain sequences that are derived from a heavy chain antibody.
  • the single variable domain or immunoglobulin single variable domain may be a (single) domain antibody (or an amino acid sequence that is suitable for use as a (single) domain antibody), a "dAb” or dAb (or an amino acid sequence that is suitable for use as a dAb) or a Nanobody (as defined herein, and including but not limited to a VHH sequence); other single variable domains, or any suitable fragment of any one thereof.
  • (single) domain antibodies reference is also made to the prior art cited herein, as well as to EP 0 368 684.
  • dAb's reference is for example made to Ward et al. (Nature 1989 Oct 12; 341 (6242): 544-6), to Holt et al. (Trends BiotechnoL, 2003, 21(l l):484-490); as well as to for example WO 04/068820, WO 06/030220, WO 06/003388 and other published patent applications of Domantis Ltd. It should also be noted that, al though less preferred in the context of the present invention because they are not of mammalian origin, single variable domains can be derived from certain species of shark (for example, the so-called "IgNAR domains", see for example WO 05/18629).
  • the immunoglobulin single variable domain may be a Nanobody® (as defined herein) or a suitable fragment thereof.
  • Nanobody®, Nanobodies® and Nanoclone® are registered trademarks of Ablynx N. V.
  • Nanobodies reference is made to the further description below, as well as to the prior art cited herein, such as e.g. described in WO 08/020079 (page 16).
  • the total number of amino acid residues in a Nanobody can be in the region of 1 10- 120, is preferably i 12-1 5, and is most preferably 1 13. It should however be noted that parts, fragments, analogs or derivatives (as further described herein) of a anobody are not particularly limited as to their length and/or size, as long as such parts, fragments, analogs or derivatives meet the further requirements outlined herein and are also preferably suitable for the purposes described herein.
  • VHH's and Nanobodies For a further description of VHH's and Nanobodies, reference is made to the review article by Muyldermans in Reviews in Molecular Biotechnology 74(2001), 277-302; as well as to the following patent applications, which are mentioned as general background art: WO 94/04678, WO 95/04079 and WO 96/34103 of the Vrije Universiteit Brussel; WO 94/25591, WO 99/37681, WO 00/40968, WO 00/43507, WO 00/65057, WO 01/40310, WO 01/44301, EP 1 134231 and WO 02/48193 of Unilever; WO 97/49805, WO 01/2181.7, WO 03/035694, WO 03/054016 and WO 03/055527 of the Vlaams Instituut voor Biotechnologie (VIB); WO 03/050531 of Aigonomics N.V.
  • Nanobodies in particular VHH sequences and partially humanized Nanobodies
  • Hallmark residues in one or more of the framework sequences.
  • Nanobodies including humanization and/or camelization of Nanobodies, as well as other modifications, parts or fragments, derivatives or "Nanobody fusions", multi valent constructs (including some non-limiting examples of linker sequences) and different modifications to increase the half-life of the Nanobodies and their preparations can be found e.g. in WO 08/101985 and WO 08/142164.
  • immunoglobulin single variable domain or “single variable domain” comprises polypeptides which are derived from a non-human source, preferably a cameiid, preferably a camel heavy chain antibody. They may be humanized, as previously described. Moreover, the term comprises polypeptides derived from non-cameiid sources, e.g. mouse or human, which have been “camelized”, as previously described.
  • immunoglobulin single variable domain encompasses immunoglobulin sequences of different origin, comprising mouse, rat, rabbit, donkey, human and cameiid immunoglobulin sequences. It also includes fully human, humanized or chimeric immunoglobulin sequences. For example, it comprises cameiid immunoglobulin sequences and humanized cameiid immunoglobulin sequences, or camelized immunoglobulin single variable domains, e.g. camelized dAb as described by Ward et al (see for example WO 94/04678 and Davics and Riechmann (1994 and 1996)).
  • immunoglobulin variable domain(s) refers to both the nucleic acid sequences coding for the polypeptide and the polypeptide per se. Any more limiting meaning will be apparent from the particular context.
  • compositions, devices and methods for the therapeutic molecules disclosed herein also include polypeptides comprising one or more protein scaffolds.
  • Protein scaffolds as used herein, includes both antibody-based scaffolds and non-antibody-based scaffolds, Protein scaffolds comprise antigen-binding polypeptides that, in turn, comprise at least one stretch of amino acid residues that correspond to an antibody CDR sequence (i.e., as part of its antigen binding site). Suitable protein scaffolds for presenting antigen-binding sequences will be clear to the skilled person.
  • Non- limiting examples of protein scaffold embraced by the invention are immunoglobulin-based scaffolds, protein scaffolds derived from protein A domains (such as AffibodiesTM), tendamistat.
  • fibronectiii lipocalin
  • CTLA-4 T-cell receptors
  • ankyrin repeats avimers and PDZ domains (Binz et al, Nat. Biotech 2005, Vol 23 : 1257), Anticalins,
  • DARPins designed ankyrin repeat proteins
  • Adnectins Adnectins
  • Chemokine binding proteins identified in ticks Affilins, CH2 domains, Centyrins (protein fold with significant structural homology to lg domains with loops analogous to CDRs) and Fynomers (single domain protein scaffolds).
  • Hosse et al. Protein Science, 2006, 15: 14-27).
  • a therapeutic molecule is any molecule, such as a polypeptide, that comprises one or more immunoglobulin variable domains, such as an immunoglobulin single variable domain, including multivalent or multispecific constructs comprising
  • a therapeutic molecule as used herein, also includes polypeptides that comprise one or more of the antibody based-scaffolds and non-antibody based scaffolds described herein. It should be appreciated that therapeutic molecules, as used herein, also include diagnostic molecules.
  • immunoglobulin (single) variable domains and/or to provide constructs that can bind to two or more different antigens, two or more immunoglobulin (single) variable domains can be combined i a single polypeptide construct, resulting in a multivalent and/or multispecific polypeptide construct.
  • the immunoglobulin (single) variable domains can be coupled to each other directly (e.g., as a fusion protein.) or using polypeptide or non-polypeptide linkers.
  • multiple binding to a target can also increase the therapeutic activity of the multivalent polypeptide relative to the individual immunoglobulin (single) variable domains.
  • Multivalency does not have to be limited to two immunoglobulin (single) variable domains, and as such, multivalent polypeptide constructs can be trimers and tetramers etc. of the same or different immunoglobulin (single) variable domains.
  • immunoglobulin (single) variable domains that bind to different targets are coupled to each other resulting in multispecific polypeptide constructs.
  • one of the immunoglobulin (single) variable domains of the multispecific polypepti de constructs binds a serum protein, thereby increasing the half-life of the polypeptide construct.
  • the serum protein is serum, albumin, serum immunoglobulin, thyroxine-binding protein, transferrin or fibrinogen.
  • the multispecific polypeptide constructs also can comprise two or more immunoglobulin (single) variable domains that bind to the same target, thereby increasing the affinity for binding to a single antigen.
  • Immunoglobulin (single) variable domains can also be coupled to polypeptides other than antibodies. Coupling of the immunoglobulin (single) variable domains to non-antibody polypeptides can provide the immunoglobuhn (single) variable domains with an extra functionality and/or can increase their half-life. Individual immunoglobulin (single) variable domains can be small and can sometimes be disposed of in the body through the kidneys. Disposal through the kidneys may diminish the therapeutic effectiveness of the immunoglobulin (single) variable domains.
  • Filtration by the kidneys can be prevented or reduced by increasing the size of individual immunoglobulin (single) variable domains through multimerization as described above or through coupling to a larger protein, preferably a stable protein found in the bloodstream, like albumin. Coupling immunoglobulin (single) variable domains to larger serum proteins will increase the half-life of the immunoglobulin (single) variable domains.
  • the serum protein is serum albumin, serum immunoglobulin, thyroxine-binding protein, transferrin or fibrinogen.
  • immunoglobulin (single) variable domains are coupled to a polypeptide that would give them additional functionalities. Examples include, but are not limited to, signaling peptides, binding peptides, peptide receptor ligands and functional, enzymes.
  • immunoglobulin (single) variable domains can also be coupled to a non -polypeptide group.
  • the non-polypeptide group is a toxic agent, in another embodiment, the non-polypeptide group is a tracer.
  • the non-polypeptide groups can be coupled to the immunoglobulin (single) variable domain through a linker as is described below.
  • Coupling the immunoglobulin (single) variable domains to a toxic agent will allow for delivery of the toxin to the antigen.
  • This methodology can be used to introduce a toxic agent to a site where it is most effective (e.g., inside a tumor cell, or on the membrane of a tumor cell).
  • the methodology can also be used to rid the bloodstream of unwanted products.
  • the immunoglobulin (single) variable domains can bind to an unwanted antigen, which can be inactivated by the toxic agent that is attached to the immunoglobulin (single) variable domains.
  • Immunoglobulin (single) variable domains can also be coupled to tracers. This will allow for the monitoring of a specific target in the body.
  • an immunoglobulin (single) variable domains that binds to a tumor antigen can be coupled to a radioactive tracer. The amount of radioactivity retained in the body and the localization of the tracer will help diagnose the amount of tumor cells in the body and can help determine the progress of a specific treatment regimen (See also below).
  • Amino acid linkers for use in multivalent and multispecific polypeptides will be clear to the skilled person, and for example include Gly-Ser linkers, for example of the type (Gly x Sei-y) z , such as for example (Gly 4 Ser) 3 or (Gly 3 Ser 2 )3, as described in WO 99/42077, hinge-like regions such as the hinge regions of naturally occurring heavy chain antibodies or similar sequences.
  • Linkers can also provide some functionality for the multivalent or multispecific polypeptides. For example, linkers containing one or more charged amino acid residues can provide improved hydrophilic properties, whereas linkers that form or contain small epitopes or tags can be used for the purposes of detection, identification and/or purification.
  • Immunoglobulin (single) variable domains can be connected to each other, to other polypeptides or to non-polypeptides groups through a number of non-peptide linkers.
  • the linker comprises an amido linker moiety, an amino linker moiety, a carbonyl linker moiety, a carbamate linker moiety, a urea linker moiety, an ether linker moiety, a disulphi.de linker moiety, a succinamidyl linker moiety, a succinyl linker moiety, and combinations thereof.
  • the linker moiety is an ester including: carbonate (-OC(O)O— ), succinoyl, phosphate esters (— 0— (O)POH-- 0— ), sulfonate esters, and combinations thereof. Diagnostics
  • semi-solid pharmaceutical compositions are used to administer immunoglobulin variable domains, such as immunoglobulin single variable domains used for diagnostics. Coupling a tracer to an immunoglobulin (single) variable domain will allow for the determination of an amount and/or location of a specific antigen in vivo or in vitro.
  • the tracer can be, but is not limited to an agent of fluorescent or radioactive origin.
  • the diagnostic administered with the semi-solid pharmaceutical, compositions can be used to determine the amount and/or location of a variety of antigens, for instance a solid tumor cell marker or peptide marker in the bloodstream. In most diagnostic assays, the diagnostics needs to be administered a set time prior to the assay. While the readout of the diagnostic assay will likely need to be performed by a health care official, being able to self administer the diagnostic dose will allow for one less trip to the clinic and savings in time and cost.
  • Immunoglobulin (single) variable domains are preferred because of their stability and small size. They could for instance enter a tumor cell, allowing for a more complete diagnostic picture.
  • immunoglobulin variable domains such as immunoglobulin single variable domains as delivered according to the methods, pharmaceutical compositions and devices of the invention.
  • exemplary diseases include inflammatory disorders, aggregation-mediated disorders, cancers, autoimmune diseases, neurodegenerative disorders, genetic disorders,
  • Inflammatory disorders include diseases such as psoriasis, rheumatoid arthritis, Crohn's disease, mastocytosis, asthmas, multiple sclerosis, inflammatory bowel syndrome and allergic rhinitis (see, e.g., US published application 2006/0058340).
  • the semi-solid pharmaceutical composition is used to administer (polypeptides comprising one or more) immunoglobulin (single) variable domains against IL-23, against TNF-alpha, against IL-6, against RANK-L, against 1L-6R, or against any other protein or target involved in the 1L ⁇ 6 pathway, as for example described in WO 2009/068627, WO 2004/041862, US 2005/0054001 , US 2006/0034845, US 60/682332, WO 03/050531, WO 03/054016, US 60/782243, US 60/782246, WO 06/122786, WO 04/003019 and WO 03/002609.
  • immunoglobulm (single) variable domains against 1L23 may be formulated as and administered using the semi-solid pharmaceutical composition disclosed herein.
  • the cancer may be a carcinoma or a sarcoma but it is not so limited.
  • the cancer may be basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma,
  • CMS cancer colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, acute lymphoid leukemia, acute myeloid leukemia, chronic lymphoid leukemia, chronic myeloid leukemia, cutaneous T-cell leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, lymphoma, follicular lymphoma, Fiodgkin's lymphoma, Non-
  • An "immune disorder” includes adult respiratory distress syndrome, arteriosclerosis, asthma, atherosclerosis, cholecystitis, cirrhosis, Crohn's disease, diabetes mellitus, emphysema, hypereosinophilia, inflammation, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, psoriasis, rheumatoid arthritis, scleroderma, and ulcerative colitis (see, e.g., US published application 2003/0175754).
  • Genetic disorders include Aarskog-Scott syndrome, Aase syndrome,
  • achondroplasia acrodysostosis, addiction, adreno-leukodystrophy, albinism, ablepharon- macrostomia syndrome, alagille syndrome, alkaptonuria, alpha- 1 antitrypsin, deficiency, Alport's syndrome, Alzheimer disease, asthma, autoimmune polyglandular syndrome, androgen insensitivity syndrome, Angelman syndrome, ataxia, ataxia telangiectasia, atherosclerosis, attention deficit hyperactivity disorder (ADHD), autism, baldness, Batten disease, Beckwith-Wiedemann syndrome, Best disease, bipolar disorder, brachydactyly, breast cancer, Burkitt lymphoma, chronic myeloid leukemia, Charcot-Marie-Tooth disease, Crohn's disease, cleft lip, Cockayne syndrome, Coffin Lowry syndrome, colon cancer, congenital adrenal hyperplasia, Cornelia de Lange syndrome, Costello syndrome, Cowden syndrome, craniofrontonasal
  • REAR syndrome Refsum disease, retinitis pigmentosa, retinoblastoma, Rett syndrome, Sanfilippo syndrome, schizophrenia, severe combined immunodeficiency, sickle cell anemia, spina bifida, spinal muscular atrophy, spinocerebellar atrophy, SRY: sex determination, sudden adult death syndrome, Tangier disease, Tay-Sachs disease, thrombocytopenia absent radius syndrome, Townes-Brocks syndrome, tuberous sclerosis, Turner syndrome, Usher syndrome, von Hippel-Lindau syndrome, Waardenburg syndrome, Weaver syndrome, Werner syndrome, Williams syndrome, Wilson's disease, xeroderma pigmentosum or Zellweger syndrome, (see, e.g., 2005/0281781).
  • molecules that can be targeted include, for example, targets of foreign origin, host derived cellular targets, and host derived non-cellular targets. Exemplary targets are listed below.
  • Foreign target agents include drugs, especially drugs subject to abuse such as heroin and other opiates, PCP, barbiturates, cocaine and derivatives thereof, benzodiazepines, etc., poisons, toxins such as heavy metals like mercury and lead, chemotherapeutic agents, paracetamol, digoxin, free radicals, arsenic, bacterial toxins such as LPS and other gram negative toxins, Staphylococcus Toxins, Toxin A, Tetanus toxins, Diphtheria toxin and Pertussis toxins, plant and marine toxins, virulence factors, such as aerobactins, radioactive compounds or pathogenic microbes or fragments thereof, including infectious viruses, such as hepatitis B, A, C, E and delta. CMV, HSV (type 3, 2 & 6), EBV, varicella zoster virus (VZV), HIV-1, -2 and other retroviruses, adenovirus, rotavirus, influenzae, rhinovirus.
  • parvovirus parvovirus, rubella, measles, polio, reovirus, orthomyxovirus, paramyxovirus, papovavirus, poxvirus and picornavirus, prions, protists such as plasmodia tissue factor, toxoplasma, filaria, kala-azar, bilharziose, entamoeba histolitica and giardia, and bacteria, particularly gram-negative bacteria responsible for sepsis and nosocomial infections such as E. coli,
  • derived cellular and non-cellular targets against to which the immunoglobulin (single) variable domains and constructs that are administered may be directed will be clear to the skilled person and for example include, but are not limited to, all targets for which NANOBODIES®, dAb's or otiier immunoglobulin variable domains (or polypeptides comprising the same) have been proposed in the art (such as IL-23, TNF-alpha, Von Wiiiebrand factor, interleukins such as 1L-6, amyloid-beta, etc., as well as the other targets mentioned in. the prior art referred to herein), as well as more generally cellular and non- cellular targets for which antibodies or antibody fragments (including but not-limited, to ScFv constructs) have been proposed in the art.
  • the present invention can be further understood with reference to steps executed to manufacture a semi-solid pharmaceutical composition in accordance with a preferred embodiment of the present invention.
  • the manufacturing flow may start by providing a water mixture that preferably contains at least water and possibly a buffer such, as e.g. a histidine or phosphate buffer.
  • the water mixture occupies at least about 70% by mass of the pharmaceutical composition.
  • various other non-oil elements are preferably mixed with, the water mixture.
  • the composition may optionally include preservatives such as e.g. potassium sorbate in small amounts.
  • Such ingredients, when included, are preferably dissolved in the water mixture.
  • the manufacturing flow preferably includes dispersing an oil based phase into the water based phase.
  • Oils and fatty components such as selected e.g. from the ones disclosed and described herein, may be used.
  • certain non-oily elements are preferably mixed with the oil phase prior to heating.
  • the cream may optionally include cetomacrogol and cetostearylalcohol or other emusifying agents.
  • cetomacrogol and cetostearylalcohol or other emusifying agents such, an ingredient, when included, is preferably mixed together with the aforementioned oils.
  • the oil phase is heated, preferably on a low heat in a double boiler, to a temperature below the boiling point of the mixture.
  • the oil mixture is then blended or otherwise mixed with, the water mixture (at approximately the same temperature) to produce the cream, thereby ending the manufacturing flow for purposes of the present invention.
  • the logic flow diagram as described herein depicts the mixing and heating of the various phases, the phases may be alternatively mixed and heated, and the oil mixture created, before or contemporaneous with creation of the water mixture. Therefore, the order of heating or/and mixing should not be interpreted to limit the appended claims in any way.
  • the therapeutic molecule can be incorporated into the semi-solid pharmaceutical composition or cream in the fonn of a liquid or in lyophilized state.
  • the therapeutic molecule is added to the cream as a liquid.
  • the therapeutic molecule is prepared in an appropriate buffer at the appropriate concentration and the liquid buffer is mixed with the cream in the appropriate amount and concentration (e.g. 0.5 mL of buffer (20 mg/mL of therapeutic molecule) is mixed with 1 gram of cream).
  • therapeutic molecule is added to the cream after lyophi zation of the therapeutic molecule. This method allows for the preparation of semi-solid formulation with higher concentrations of therapeutic molecule.
  • the lyophilized therapeutic molecule is mixed with the cream in the appropriate amounts. Definitions
  • a “stable" semi-solid pharmaceutical composition is one in which the protein such as the immunoglobulin single variable domain or a construct thereof retains its physical and chemical stability and integrity upon storage.
  • Various analytical techniques for measuring protein stability are available in the art. Stability can be measured at a selected temperature for a selected time period. For rapid screening, the pharmaceutical composition may be kept at 37 ⁇ 40°C for 2 weeks to 1 month, at which time protein stability is measured.
  • the phaiTnaceutical composition is to be stored at 2 to 8 °C, generally depending on the intended shelve life the phaiTnaceutical composition should e.g. be stable at 30°C or 37-40°C for at least one month and/or stable for at least 2 years at 2 to 8 °C.
  • the extent of aggregation may be one wherein less than about 10% and preferably less than about 5% of the protein is present as an aggregate in the pharmaceutical composition.
  • Aggregation as used in the present invention means the development of high molecular weight aggregates, i.e. aggregates with an apparent molecular weight of more/higher than the apparent molecular weight observed in SE-HPLC analysis for the therapeutic molecule of the invention in comparison with molecular weight markers.
  • Aggregation can be assessed by various methods known in the art. Without being limiting, examples include high performance size exclusion chromatography (SEC), subvisible particle counting, analytical uitracentrifugation (AUC), dynamic light scattering (DLS), static light scattering (SLS), elastic light scattering, OD320/OD280 measurement, Fourier Transform Infrared Spectroscopy (FTIR), circular dichroism (CD), urea-induced protein unfolding techniques, intrinsic tryptophan fluorescence and/or differential scanning calorimetry techniques.
  • SEC size exclusion chromatography
  • AUC analytical uitracentrifugation
  • DLS dynamic light scattering
  • SLS static light scattering
  • OD320/OD280 measurement Fourier Transform Infrared Spectroscopy
  • CD circular dichroism
  • urea-induced protein unfolding techniques intrinsic tryptophan fluorescence and/or differential scanning calorimetry techniques.
  • any increase in aggregate formation following lyophilization and storage of the lyophilized pharmaceutical composition can be determined.
  • a "stable" lyophilized pharmaceutical composition may be one wherein the increase in aggregate in the lyophilized composition is less than about 10% and preferably less than about 5%, when the lyophilized composition is stored at 2 to 8 °C for at least 8 weeks, preferably at least one year.
  • the pharmaceutical composition may be kept at 37-40°C for 2 weeks to 1 month, at which time protein stability, is measured.
  • a "stable" lyophilized pharmaceutical composition may be one wherein the increase in aggregate in the lyophilized composition is less than about 10% and preferably less than about 5%, when the lyophilized composition is stored at 37-40 °C for 2 weeks to one month.
  • stability of the pharmaceutical composition may be measured using a biological assay.
  • the potency and/or biological activity of a biological or therapeutic molecule describes the specific ability or capacity of said biological or therapeutic molecule to achieve a defined biological effect.
  • the potency and biological activities of the therapeutic molecules of the invention can be assessed by various assays including any suitable in vitro assay, cell-based assay, in vivo assay and/or animal model known per se, or any combination thereof, depending on the specific disease or disorder involved.
  • Suitable in vitro assays will be clear to the skilled person, and for example include ELISA; FACS binding assay; Biacore; competition binding assay (AlphaScreen®, Perkin Elmer, Massachusetts, USA; FMAT); SEQ ID NO's: 1 to 3 interact with IL-23 and block the interaction, of this ligand with its receptor.
  • the potency of SEQ ID NO's: 1 to 3 for blocking the respective ligand/receptor interaction can be determined, e.g. by ELISA, Biacore, AlphaScreen®.
  • Biacore kinetic analysis uses Surface Plasmon Resonance (SPR) technology to monitor macromolecular interactions in real time and is used to determine the binding on and off rates of polypeptides of the formulation of the invention to their target.
  • Biacore kinetic analysis comprises analyzing the binding and dissociation of the target from chips with immobilized polypeptides of the invention on their surface.
  • a typical Biacore kinetic study invoives the injection of 250 ⁇ , of polypeptide reagent at varying concentration in HBS buffer containing 0.005% Tween 20 over a sensor chip surface, onto which has been immobilized the antigen.
  • the ligand is immobilized on carboxymethylated dextran over a gold surface, while the second partner (analyte) is captured as it flows over the immobilized ligand surface.
  • the immobilized ligands are remarkably resilient and maintain their biological activity.
  • the bound analytes can be stripped from the immobilized ligand without affecting its activity to allow many cycles of binding and regeneration on the same immobilized surface. Interaction is detected in real time via SPR and at high sensitivity. Because the same affinity may reflect different on-rates and off -rates, this instrument excels over most other affinity measuring methods in that it measures on-rates (ka) and off-rates (kd). Concentration determination experiments arc also feasible.
  • the semi-solid formulations of the present invention exhibits almost no loss in biological activities and/or potency of the therapeutic molecules during the prolonged storage under the conditions described above, as assessed by various immunological assays including, for example, enzyme-linked immunosorbent assay (ELISA).
  • the therapeutic molecules in the semi-solid formulations of the present invention retain, even under the above defined stress conditions (such as storage under certain temperature stress for defined periods) more than 80%, more than 85%, more than 90%, more than 95%, more than 98%, more than 99%, or more than 99.5% of their initial biological activities and/or potencies (e.g., the ability to bind IL-23 and/or HSA) of the therapeutic molecule prior to the storage.
  • the polypeptides in the formulation of the invention retain under the above defined stress conditions at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% of the biological activity and/or potency (e.g., the ability to bind to IL-23 and/or HSA) compared to the therapeutic molecules present in a reference formulation prior to the storage.
  • the biological activity and/or potency e.g., the ability to bind to IL-23 and/or HSA
  • a “stable" pharmaceutical composition can be one wherein the loss in potency in a biological assay is less than 10%, preferably less than about 5% when the composition is stored at 2 to 8 °C for at least 8 weeks, preferably at least one year.
  • the pharmaceutical composition may be kept at 37-40°C for 2 weeks to 1 month, at which time protein stability is measured.
  • a “stable” pharmaceutical composition can be one wherein the loss in potency is less than 30%, less than 25%, preferably less than 20%, less than 1 %, most preferably less than 10%, less than 5% when the composition is stored at 37-40 °C for 2 weeks to one month.
  • "Semisolid" pharmaceutical systems comprise a body of products, which when applied to the skin or accessible mucous membranes tend to alleviate or treat a pathological condition or offer protection against a harmful environment. They have the property to cling to the skin or mucous membrane for a protracted period of time to e ert their therapeutic effect through protection and occlusion.
  • “Semisolid” dosage forms usually are intended for localized, drug delivery. In the past few years, however, these forms also have been explored for the systemic delivery of various drugs. They can. be applied topically to the skin, cornea, rectal tissue, nasal mucosa, vagina, buccal tissue, urethral membrane, and external ear lining (ref: Encyclopedia of Pharmaceutical Technology, third edition, 2006, ISBN: 978-0-8493-9399-0 (hardback) 978- 0-8493-9398-3 (electronic)).
  • Example 1 Semi-solid pharmaceutical compositions comprising anti-IL23 Nanobody constructs
  • Example la Lyophilisation of Nanobody constructs P23IL0Q75, P23IL0087 and P23IL0095
  • the protein was concentrated and buffer-excha ged by cross flow to a concentration of approximately 20 mg/niL in a 10 mM histidine pH6 buffer with 10 % sucrose. Aliquots of 2.5 mL were Iyophilized in 6R vials using an EPSILON 2-4 LSC
  • the incorporation of the Nanobody in the cream was performed as follows: 120 to
  • the SE-HPLC assay consisted of a pre-packed silica gel TSKgel G2000SW XL column equipped with a guard column pre-column filter, a mobile phase consisting of 10 mM Na Phosphate, 0.3M arginine and 0.005%NaN 3 at pH6, and UV detection at 280 nm.
  • the relative amount of protein purity was expressed as area %, and was calculated by dividing the peak area by the total integrated area.
  • RP-HPLC assay a Zorbax 300SB-C8 column (Agilent Technologies, Palo Alto, US) was used. The amount of the protein was determined by measuring the light absorbance of the components eluting from the RP-HPLC column and comparison with a reference sample. The identity of the Nanobody constructs was confirmed by comparing the relative elution time from the RP-HPLC column. The relative amount of protein purity was expressed as area %, and was calculated by dividing the peak area by the total (main peak + impurities) integrated area.
  • Example 3.3 Analysis of the integrity of the anti-IL23 Nanobodies after yophilization. incorporation and storage in a cream
  • the recovery of the Nanobody construct was calculated as if all of the Nanobody construct in the cream would be extracted by the 1 mL PBS volume. In case the creams were made from lyophilized powder, the recovery was between 76 and 83%. One exception was the cream analyzed after 4 weeks storage at 25°C, which was concentrated due to evaporation during storage. In case the cream was made with the liquid formulation, the extraction recovery was close to 100 %. The extraction recoveries were calculated based on the RPC peak area's for quantification of the Nanobody concentration in the extract. These concentrations were also used for the potency analysis.
  • Example 4 Potency analysis of anti-IL-23 Nanobody following lyophilization and formulation into cream
  • the potency of the anti-hIL-23 Nanobody construct P23ILO075 was analyzed after lyophilisation and after formulation as lyophilized material into cetomacrogol cream (20 mg g). Therefore, analysis was performed in a neutralization ELISA, measuring the potency of the IL-23 binding moieties of P23IL0075 Nanobody construct for their capacity to inhibit the interaction of human IL-23 to a hIL-23R-Fc chimera. Briefly, 96-well microliter plates were coated overnight at 4°C with anti-Fc Nanobody and blocked for 30 min with
  • rhIL-23 was detected for 45 min at RT with a 1/4000 dilution of biotin.yi.ated anti-human IL-12 p40/p70 monoclonal antibody (eBiosciences, 13-7129) in PBS containing 1 % Superblock T20, followed by a 30 min incubation at RT with 0.067 ⁇ g/mL Strep-HRP (Thermo Scientific, 21126) in PBS containing 10% Superblock T20. Visualization was obtained with (undiluted) esTMB (SDT reagents Gemiany) and the coloring reaction was stopped by adding IN HCL after which the optical density was measured at 450nm.
  • biotin.yi.ated anti-human IL-12 p40/p70 monoclonal antibody eBiosciences, 13-7129
  • Strep-HRP Thermo Scientific, 21126
  • the potency of P23IL0075 after lyophilisation followed by subsequent reconstitution in. PBS was compared with the potency of the P23IL0075 reference batch formulated as liquid solution in l OmM pH6 Histidine + 10% sucrose buffer.
  • the potency of P23IL0075 was verified after formulation of lyophilized material into cream (20 mg/g) followed by subsequent extraction in PBS.
  • HSA human serum albumin
  • ALB albumin-binding moiety
  • Example 5 Stability analysis of anti lilL-23 Nanobody formulated in cetomacrogoi creams by means of potency determination
  • the stability of the anti-hIL ⁇ 23 Nanobodies P23IL0075 and P23IL0087 as formulated in cream (20mg/g) was analyzed in the inhibition, potency EL1SA and HSA binding ELISA, as described in Example 4. Therefore, the potency of P23IL0075 was determined following extraction, after 2 and 8 weeks storage at 4°C, from the cream formulation. In addition, the potency of P23IL0075 was verified after processing the Nanobody reference batch directly into the cream without a lyophilisation step.
  • GGTTC TACGACTCTTGGGGACAGGGAACTCTGGTCACCGTCTCCTCA
  • P23IL0O95 is SEQ ID NO: 6 GAGGTGCaattgctggagtCtgggGGAGGATTGGTACAACCAGGAGGTTCTTTGAGACTGTCTTGTGCAGCTTC TGGTCGTATATTCAGTTTGCCTGCTAGTGGGAATATTTTTAACCTGCTCACTATCGCTTGGTATCGTCAAGCTC CAGGTAAAGGTAGAGAGCTTGTTGCCACGATTAACTCTGGTTCCAGGACATATTACGCTGATAGCGTTAAGGGC AGATTCACAATCTCGCGAGATAATTCGAAAAAAACTGTTTACCTGCAAATGAACAGCCTTAGACCAGAAGATAC TGCCGTCTATTACTGTCAAACTTCAGGGTCTGGTAGTCCCAACTTTTGGGGTCAAgggaccctggtcacggtCt cctcaggaggtggcggatcggcggaggaggtagtGGTGGTGGAGGTTCTGGTGGTGGAGGATCAGGTGGAGGTGGAAGTGGAGGTGG
  • Table 2 Overview of the QC data on the Nanobody constructs during the different steps of formulation.
  • the iyophilized samples were reconstituted to their original volume with MQ water, and the creams were extracted with PBS prior to analysis
  • Tabic 5 Overview of the stability data obtained after storage of the creams up to 8 weeks at 4°C and up to 4 weeks at 25°C
  • n.a. Not Analyzed Tabic 3. Overview of the IC50 values (nM) of the P23IL0075 Nanobody construct in the IL-23/IL-23R inhibition potency ELISA before and after lyophilisation, and after formulation in cream. Lower limits and upper limits of the 95% confidence interval
  • T able 9. Overview of the IC50 values (nM) of th P23IL0075 Nanobody construct in the IL-23/IL-23R inhibition potency ELISA before and after a 2 week formulation in cream. Lower limits and upper limits of the 95% confidence interval (LLCl and ULCI) are indicated.
  • Table I Overview of the EC50 values (nM) of the P23IL0075 Nanobody construct in the HSA binding potency ELISA before and after formulation in cream after storage for 2 or 8 weeks at 4°C. Lower limits and upper limits of the 95% confidence interval (LLCl and ULCI) are indicated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne le domaine de compositions pharmaceutiques semi-solides destinées à une administration sur la peau, comprenant des domaines variables simples de l'immunoglobuline ou leurs produits de recombinaisons.
PCT/EP2011/060699 2010-06-25 2011-06-27 Compositions pharmaceutiques destinées à une administration par voie cutanée Ceased WO2011161263A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35858810P 2010-06-25 2010-06-25
US61/358,588 2010-06-25

Publications (1)

Publication Number Publication Date
WO2011161263A1 true WO2011161263A1 (fr) 2011-12-29

Family

ID=44627463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/060699 Ceased WO2011161263A1 (fr) 2010-06-25 2011-06-27 Compositions pharmaceutiques destinées à une administration par voie cutanée

Country Status (1)

Country Link
WO (1) WO2011161263A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654924B2 (en) 2015-01-12 2020-05-19 Crescendo Biologics Limited IL-17A binding proteins
WO2024133935A1 (fr) 2022-12-23 2024-06-27 Ablynx Nv Excipients de conjugaison protéiques
WO2024170756A1 (fr) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides se liant au récepteur fc néonatal

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684A1 (fr) 1988-11-11 1990-05-16 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
WO1994025591A1 (fr) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE)
WO1995004079A1 (fr) 1993-08-02 1995-02-09 Raymond Hamers Vecteur recombinant contenant une sequence d'un gene de lipoproteine pour l'expression de sequences de nucleotides
WO1996034103A1 (fr) 1995-04-25 1996-10-31 Vrije Universiteit Brussel Fragments variables d'immunoglobulines et leur utilisation dans un but therapeutique ou veterinaire
WO1997049805A2 (fr) 1996-06-27 1997-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Molecules de reconnaissance ayant une interaction specifique avec le site actif ou la fissure d'une molecule cible
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
WO1999023221A2 (fr) 1997-10-27 1999-05-14 Unilever Plc Proteines multivalentes de fixation de l'antigene
WO1999037681A2 (fr) 1998-01-26 1999-07-29 Unilever Plc Procede servant a preparer des fragments d'anticorps
WO1999042077A2 (fr) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions et procedes de regulation de l'activation des lymphocytes
WO2000040968A1 (fr) 1999-01-05 2000-07-13 Unilever Plc Fixation de fragments d'anticorps a des supports solides
WO2000043507A1 (fr) 1999-01-19 2000-07-27 Unilever Plc Procede de production de fragments d'anticorps
WO2000065057A1 (fr) 1999-04-22 2000-11-02 Unilever Plc Inhibition d'une infection virale au moyen de proteines de liaison a l'antigene monovalentes
WO2001021817A1 (fr) 1999-09-24 2001-03-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Phages recombinants capables de penetrer dans des cellules hotes via une interaction specifique avec un recepteur artificiel
WO2001040310A2 (fr) 1999-11-29 2001-06-07 Unilever Plc Immobilisation de proteines
WO2001044301A1 (fr) 1999-11-29 2001-06-21 Unilever Plc Immobilisation de molecules de liaison d'antigene a domaine unique
EP1134231A1 (fr) 2000-03-14 2001-09-19 Unilever N.V. Domaines variables de la chaine lourde d'anticorps contre des enzymes humaines alimentaires et leurs utilisations
WO2001090190A2 (fr) 2000-05-26 2001-11-29 National Research Council Of Canada Fragments d'anticorps de fixation d'antigenes monodomaines, derives d'anticorps de lamas
WO2002048193A2 (fr) 2000-12-13 2002-06-20 Unilever N.V. Réseaux de protéines
WO2002089917A2 (fr) * 2001-05-09 2002-11-14 Karo Bio Ab Preparations dermatologiques
WO2003002609A2 (fr) 2001-06-28 2003-01-09 Domantis Limited Ligand
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
WO2003035694A2 (fr) 2001-10-24 2003-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Anticorps fonctionnels a chaine lourde, fragments de ces derniers, bibliotheque de ces derniers et procedes de production
WO2003050531A2 (fr) 2001-12-11 2003-06-19 Algonomics N.V. Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes
WO2003054016A2 (fr) 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Procede de clonage de sequences de domaines variables
WO2003055527A2 (fr) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Nouveaux immunoconjugues utiles pour le traitement de tumeurs
US20030147890A1 (en) * 1997-06-23 2003-08-07 Ye George Qing Wei Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US20030175754A1 (en) 1998-06-29 2003-09-18 Incyte Genomics, Inc. RVP-1 variant differentially expressed in crohns disease
WO2004003019A2 (fr) 2002-06-28 2004-01-08 Domantis Limited Ligand
WO2004041865A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique stabilises
WO2004041867A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Procede d'administration de polypeptides therapeutiques et polypeptides associes
WO2004062551A2 (fr) 2003-01-10 2004-07-29 Ablynx N.V. Polypeptides therapeutiques, leurs homologues, leurs fragments, que l'on utilise dans la modulation de l'agregation plaquettaire
WO2004068820A2 (fr) 2003-01-23 2004-08-12 Unspam, Llc. Procede et appareil destines a un systeme de liste de numeros interdits a ne pas divulguer
WO2005018629A1 (fr) 2003-08-12 2005-03-03 Yarbrough William M Traitement de l'acne simple et procede d'utilisation
WO2005044858A1 (fr) 2003-11-07 2005-05-19 Ablynx N.V. Polypeptide vhh de camelidae, anticorps a domaine unique diriges contre le recepteur de facteur de croissance epidermique et utilisations de ceux-ci
US20050281781A1 (en) 2004-06-16 2005-12-22 Ostroff Gary R Drug delivery product and methods
WO2006003388A2 (fr) 2004-06-30 2006-01-12 Domantis Limited Compositions et procedes pour le traitement de troubles inflammatoires
US20060019923A1 (en) 2004-07-18 2006-01-26 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20060058340A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity
WO2006030220A1 (fr) 2004-09-17 2006-03-23 Domantis Limited Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
WO2006079372A1 (fr) 2005-01-31 2006-08-03 Ablynx N.V. Procede de generation de sequences a domaine variable d'anticorps a chaine lourde
WO2006122787A1 (fr) 2005-05-18 2006-11-23 Ablynx Nv Proteines de liaison a l'albumine serique
WO2006122825A2 (fr) 2005-05-20 2006-11-23 Ablynx Nv 'nanobodies™' (nanocorps) perfectionnes pour traiter des troubles medies par une agregation
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
WO2008101985A2 (fr) 2007-02-21 2008-08-28 Ablynx N.V. Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
WO2008142164A2 (fr) 2007-05-24 2008-11-27 Ablynx N.V. Séquences d'acides aminés dirigées contre rank-l et polypeptides comprenant ces dernières, destinés au traitement de maladies et affections osseuses
WO2009068627A2 (fr) 2007-11-27 2009-06-04 Ablynx N.V. Séquences d'acides aminés dirigés contre des cytokines hétérodimères et/ou leurs récepteurs et polypeptides les comprenant
WO2009095235A1 (fr) 2008-01-29 2009-08-06 Ablynx N.V. Procédés de stabilisation de protéines et de polypeptides
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
WO2011026948A1 (fr) 2009-09-03 2011-03-10 Ablynx N.V. Formulations stables de polypeptides et leurs utilisations

Patent Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684A1 (fr) 1988-11-11 1990-05-16 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
WO1994025591A1 (fr) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE)
WO1995004079A1 (fr) 1993-08-02 1995-02-09 Raymond Hamers Vecteur recombinant contenant une sequence d'un gene de lipoproteine pour l'expression de sequences de nucleotides
WO1996034103A1 (fr) 1995-04-25 1996-10-31 Vrije Universiteit Brussel Fragments variables d'immunoglobulines et leur utilisation dans un but therapeutique ou veterinaire
WO1997049805A2 (fr) 1996-06-27 1997-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Molecules de reconnaissance ayant une interaction specifique avec le site actif ou la fissure d'une molecule cible
US7147854B2 (en) 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US20030147890A1 (en) * 1997-06-23 2003-08-07 Ye George Qing Wei Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
WO1999023221A2 (fr) 1997-10-27 1999-05-14 Unilever Plc Proteines multivalentes de fixation de l'antigene
WO1999037681A2 (fr) 1998-01-26 1999-07-29 Unilever Plc Procede servant a preparer des fragments d'anticorps
WO1999042077A2 (fr) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions et procedes de regulation de l'activation des lymphocytes
US20030175754A1 (en) 1998-06-29 2003-09-18 Incyte Genomics, Inc. RVP-1 variant differentially expressed in crohns disease
WO2000040968A1 (fr) 1999-01-05 2000-07-13 Unilever Plc Fixation de fragments d'anticorps a des supports solides
WO2000043507A1 (fr) 1999-01-19 2000-07-27 Unilever Plc Procede de production de fragments d'anticorps
WO2000065057A1 (fr) 1999-04-22 2000-11-02 Unilever Plc Inhibition d'une infection virale au moyen de proteines de liaison a l'antigene monovalentes
WO2001021817A1 (fr) 1999-09-24 2001-03-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Phages recombinants capables de penetrer dans des cellules hotes via une interaction specifique avec un recepteur artificiel
WO2001040310A2 (fr) 1999-11-29 2001-06-07 Unilever Plc Immobilisation de proteines
WO2001044301A1 (fr) 1999-11-29 2001-06-21 Unilever Plc Immobilisation de molecules de liaison d'antigene a domaine unique
EP1134231A1 (fr) 2000-03-14 2001-09-19 Unilever N.V. Domaines variables de la chaine lourde d'anticorps contre des enzymes humaines alimentaires et leurs utilisations
WO2001090190A2 (fr) 2000-05-26 2001-11-29 National Research Council Of Canada Fragments d'anticorps de fixation d'antigenes monodomaines, derives d'anticorps de lamas
WO2002048193A2 (fr) 2000-12-13 2002-06-20 Unilever N.V. Réseaux de protéines
WO2002089917A2 (fr) * 2001-05-09 2002-11-14 Karo Bio Ab Preparations dermatologiques
WO2003002609A2 (fr) 2001-06-28 2003-01-09 Domantis Limited Ligand
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
EP1433793A1 (fr) 2001-09-13 2004-06-30 Institute for Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
WO2003035694A2 (fr) 2001-10-24 2003-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Anticorps fonctionnels a chaine lourde, fragments de ces derniers, bibliotheque de ces derniers et procedes de production
US20050054001A1 (en) 2001-10-24 2005-03-10 Serge Muyldermans Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
WO2003050531A2 (fr) 2001-12-11 2003-06-19 Algonomics N.V. Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes
WO2003054016A2 (fr) 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Procede de clonage de sequences de domaines variables
WO2003055527A2 (fr) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Nouveaux immunoconjugues utiles pour le traitement de tumeurs
WO2004003019A2 (fr) 2002-06-28 2004-01-08 Domantis Limited Ligand
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
WO2004041862A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
WO2004041867A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Procede d'administration de polypeptides therapeutiques et polypeptides associes
WO2004041863A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
WO2004041865A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique stabilises
WO2004062551A2 (fr) 2003-01-10 2004-07-29 Ablynx N.V. Polypeptides therapeutiques, leurs homologues, leurs fragments, que l'on utilise dans la modulation de l'agregation plaquettaire
WO2004068820A2 (fr) 2003-01-23 2004-08-12 Unspam, Llc. Procede et appareil destines a un systeme de liste de numeros interdits a ne pas divulguer
WO2005018629A1 (fr) 2003-08-12 2005-03-03 Yarbrough William M Traitement de l'acne simple et procede d'utilisation
WO2005044858A1 (fr) 2003-11-07 2005-05-19 Ablynx N.V. Polypeptide vhh de camelidae, anticorps a domaine unique diriges contre le recepteur de facteur de croissance epidermique et utilisations de ceux-ci
US20050281781A1 (en) 2004-06-16 2005-12-22 Ostroff Gary R Drug delivery product and methods
US20060058340A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity
WO2006003388A2 (fr) 2004-06-30 2006-01-12 Domantis Limited Compositions et procedes pour le traitement de troubles inflammatoires
US20060019923A1 (en) 2004-07-18 2006-01-26 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
WO2006030220A1 (fr) 2004-09-17 2006-03-23 Domantis Limited Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
WO2006079372A1 (fr) 2005-01-31 2006-08-03 Ablynx N.V. Procede de generation de sequences a domaine variable d'anticorps a chaine lourde
WO2006122786A2 (fr) 2005-05-18 2006-11-23 Ablynx Nv Nanocorpstm; utilises contre le facteur-alpha de necrose tumorale
WO2006122787A1 (fr) 2005-05-18 2006-11-23 Ablynx Nv Proteines de liaison a l'albumine serique
WO2006122825A2 (fr) 2005-05-20 2006-11-23 Ablynx Nv 'nanobodies™' (nanocorps) perfectionnes pour traiter des troubles medies par une agregation
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
WO2008101985A2 (fr) 2007-02-21 2008-08-28 Ablynx N.V. Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
WO2008142164A2 (fr) 2007-05-24 2008-11-27 Ablynx N.V. Séquences d'acides aminés dirigées contre rank-l et polypeptides comprenant ces dernières, destinés au traitement de maladies et affections osseuses
WO2009068627A2 (fr) 2007-11-27 2009-06-04 Ablynx N.V. Séquences d'acides aminés dirigés contre des cytokines hétérodimères et/ou leurs récepteurs et polypeptides les comprenant
WO2009095235A1 (fr) 2008-01-29 2009-08-06 Ablynx N.V. Procédés de stabilisation de protéines et de polypeptides
WO2011026948A1 (fr) 2009-09-03 2011-03-10 Ablynx N.V. Formulations stables de polypeptides et leurs utilisations

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Phannaceutical Technology", 2006
BINZ ET AL., NAT. BIOTECH, vol. 23, 2005, pages 1257
CONRATH ET AL., J. BIOL. CHEM., vol. 276, no. 10, 2001, pages 7346 - 7350
DAVIES, RIECHMANN, FEBS LETT., vol. 339, 1994, pages 285 - 290
HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, 2003, pages 484 - 490
HOSSE ET AL., PROTEIN SCIENCE, vol. 15, 2006, pages 14 - 27
MUYLDERMANS ET AL., TIBS, vol. 26, no. 4, 2001, pages 230 - 235
MUYLDERMANS, REVIEWS IN MOLECULAR BIOTECHNOLOGY, vol. 74, 2001, pages 277 - 302
PROT. ENG., vol. 9, no. 6, 1996, pages 531 - 537
WARD ET AL., NATURE, vol. 341, no. 6242, 12 October 1989 (1989-10-12), pages 544 - 6

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654924B2 (en) 2015-01-12 2020-05-19 Crescendo Biologics Limited IL-17A binding proteins
US11667705B2 (en) 2015-01-12 2023-06-06 Crescendo Biologics Limited IL-17A binding proteins
WO2024133935A1 (fr) 2022-12-23 2024-06-27 Ablynx Nv Excipients de conjugaison protéiques
WO2024170756A1 (fr) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides se liant au récepteur fc néonatal

Similar Documents

Publication Publication Date Title
US20220380445A1 (en) Serum albumin binders
AU2016351710B2 (en) Improved serum albumin-binding immunoglobulin variable domains
US20230050615A1 (en) Improved serum albumin binding immunoglobulin single variable domains
US20240294617A1 (en) Serum albumin binders
US12492239B2 (en) Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
CN104231082B (zh) 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
US20130012916A1 (en) Delivery of immunoglobulin variable domains and constructs thereof
US20190367597A1 (en) Serum albumin binders
AU2007293614A1 (en) Serum albumin binding proteins with long half-lives
CN110418803A (zh) 抗rsv单克隆抗体配制品
WO2009080764A2 (fr) Administration orale ou nasale de composés comprenant des séquences d'acides aminés
JP2024528724A (ja) 抗ｐｄ－１抗体医薬組成物及びその使用
WO2011161263A1 (fr) Compositions pharmaceutiques destinées à une administration par voie cutanée
KR20230010239A (ko) 항-il-33 항체의 제형물
JP7315259B2 (ja) 百日咳毒素結合タンパク質
CN116725961A (zh) 抗cd39抗体药物组合物及其用途
CA3005061C (fr) Domaines variables d'immunoglobuline de liaison amelioree a l'albumine serique
WO2023142109A1 (fr) Hormone de croissance humaine recombinante à action prolongée et son utilisation
HK40109650A (zh) 制剂
CN116803420A (zh) 靶向PD-1和TGFβ的双功能蛋白药物组合物及其用途
WO2025026216A1 (fr) Composition pharmaceutique contenant un conjugué anticorps-médicament de glucocorticoïde

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11727470

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11727470

Country of ref document: EP

Kind code of ref document: A1